MRD-guided immunotherapy plus chemo after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and have non-small cell lung cancer (NSCLC) confirmed by pathology
- Have had your tumor completely removed by surgery, and your stage is IIA, IIB, IIIA, or IIIB (T3N2)
- Provide enough tissue samples (fresh frozen or stored pathology slides) for MRD testing
- Be able to do study visits and tests, and have an ECOG activity score of 0 or 1
- Have not had certain prior immune medicines (like anti–PD-1/PD-L1 or anti–CTLA-4) or other systemic immune-modulating treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
This trial tests whether adding an extra interventional treatment after surgery helps for lung cancer that has a high chance of returning, as shown by a positive minimal residual disease (MRD) test. The goal is to see if this approach can reduce the risk of the cancer coming back.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.